Oligomeric Compounds Reducing ATXN2 Expression for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism are inadequate, as they fail to effectively reduce the toxicity associated with polyglutamine expansion in the ataxin-2 protein, which contributes to neuronal loss and aggregate formation.
Innovation Solution
Development of oligomeric compounds, specifically modified oligonucleotides, that target and reduce the expression of ATXN2 RNA, thereby decreasing the levels of Ataxin-2 protein, using complementary sequences to hybridize with ATXN2 nucleic acid and inhibit its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative diseases, then they are administered to patients, but they fail to effectively reduce polyglutamine expansion toxicity and Ataxin-2 protein levels
Solution Approach 1:
The patent extracts and targets the specific pathogenic element (ATXN2 RNA) responsible for polyglutamine expansion toxicity. By using complementary oligonucleotide sequences that specifically bind to ATXN2 RNA, the treatment selectively removes or silences the harmful RNA transcript, thereby reducing toxic Ataxin-2 protein production without affecting other cellular functions.
Solution Approach 2:
The patent introduces complementary oligonucleotide sequences as intermediary molecules that mediate between the therapeutic goal and the target. These oligonucleotides act as mediators by hybridizing to ATXN2 RNA, forming stable complexes that prevent translation of the toxic protein while allowing for controlled degradation or silencing of the RNA transcript.
2Reliability
If oligomeric compounds are used to reduce ATXN2 RNA expression, then Ataxin-2 protein levels decrease, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent employs complementary oligonucleotide sequences that serve multiple functions: they specifically recognize and bind to ATXN2 RNA through sequence complementarity, induce RNA silencing or degradation, and can be administered systemically. This multi-functionality reduces the need for multiple separate therapeutic agents or complex delivery systems.
Solution Approach 2:
The patent uses synthetic oligonucleotide copies of the complementary sequence to ATXN2 RNA. These synthetic copies are designed to perfectly match the target RNA sequence, enabling specific binding and silencing. The copying approach allows for precise control of specificity and affinity while simplifying the therapeutic mechanism compared to protein-based therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution effectively ameliorates symptoms of neurodegenerative diseases by reducing Ataxin-2 protein levels, improving motor function, reducing neuropathy, and decreasing aggregate formation, providing a therapeutic benefit for patients with SCA2, ALS, and parkinsonism.
Implementation Method 1
using complementary sequences to hybridize with ATXN2 nucleic acid and inhibit its activity
Data Source
AI summary
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN2 RNA in a cell or animal, and in certain instances reducing the amount of Ataxin-2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.